Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 34

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 (226,504)  (616,172)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(164,108) $(225,560)  (226,504) $(616,172)

 25Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

   Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total    Three month period ended June 30, 2024               REVENUE  $5,496  $1,969,068  $-  $1,974,564                   COST OF REVENUE   (2,353)  (1,683,491)  -   (1,685,844)                  GROSS PROFIT   3,143   285,577   -   288,720                   OTHER INCOME                 Dividend income    -   11,881   -   11,881 Interest income   37,154   12,585   -   49,739 Fair value gain on investments in equity securities   -   88,532   -   88,532 Gain on disposal of investments in equity securities   -   8,117   -   8,117 Reversal of expected credit losses   -   552,663   -   552,663 Others   210   18,963   -   19,173 TOTAL OTHER INCOME   37,364   692,741   -   730,105                   OPERATING EXPENSES                 Sales and marketing   (23,011)  (103,257)  (10,226)  (136,494)Research and development   (8,198)  -   -   (8,198)General and administrative   (73,154)  (121,741)  (363